Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX), and a Neutral ...

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

On May 21, 2025, the Federal Trade Commission (FTC) issued its third round of warning letters – and its first under the Trump administration – ...

Teva Pharmaceutical Industries (TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting ...

A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and ...

Teva got more time to ask the Supreme Court to review a ruling that could strip hundreds of drug patents from a key FDA registry, a decision the company says could reshape how makers of brand-name ...